Long-Term Setmelanotide for Obesity

"Setmelanotide is an effective chronic weight management therapy for patients with obesity, especially those with POMC deficiency obesity."

"The drug setmelanotide was first studied at the Marshfield Clinic Research Institute in 2018. There have been a total of 12 completed clinical trials since then, with 4 more currently ongoing. A large number of these live trials are based out of Nashville, Tennessee."

"There have been a total of 4 studies completed for Setmelanotide as of now. They were conducted in 31 cities across 9 different countries, with the first study taking place in 2018. The initial trial was sponsored by Rhythm Pharmaceuticals, Inc. and involved 150 patients. It successfully completed its Phase 2 & 3 drug approval stages. Since then, an additional 12 trials have been carried out."

"The clinical trial is currently recruiting patients, as denoted by information available on clinicaltrials.gov. This research was originally posted on July 15th, 2018 with the most recent update occurring November 9th, 2022."

"As of now, 20 patients have been enrolled in the trial with locations including Vanderbilt University Medical Center in Nashville, Honor Health Research Institute in Scottsdale, Obesity Institute at Geisinger Clinic in Danville, and other centres."

"That is correct. The clinical trial, which began recruitment on July 15th 2018, is still seeking 150 participants from 20 different sites, according to the latest information available on clinicaltrials.gov."